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Abstract:
Purpose: To develop a imaging technology for protease activities in patients that could help in prognosis prediction and in design of personalized protease-based inhibitors and prodrugs for targeted therapy.
Experimental Design: Polyethylene glycol (PEG) was covalently attached to the N-terminus of a hydrophilic peptide substrate (GPLGVR) for matrix metalloproteinase (MMP) to increase hydrophilicity. PEG-peptide was then linked to a hydrophobic tetramethylrhodamine (TMR) domain and labeled with 18 F to form a PEG-peptide- 18 F-TMR probe. Specific cleavage of the probe by MMP2 was tested in vitro by matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF). In vivo imaging of MMP2-expressing tumors was evaluated by micro-PET.
Results:
The hydrophobic TMR fragment (948 Da) was specifically generated by MMP2 enzymes and MMP-expressing HT1080 cells but not control MCF-7 cells.
MMP-expressing HT1080 cells and tumors selectively accumulated the hydrolyzed, hydrophobic TMR fragment at sites of protease activity. Importantly, we found that These results suggest that the PEG-peptide- 18 F-TMR probe displays high selectivity for imaging MMP activity.
Conclusions:
This strategy successfully image MMP expression in vivo, may be extended to other proteases to predict patient prognosis and to design personalized, protease-based inhibitors and prodrug targeted therapies.
Research.
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Translational Relevance
Development of a non-inhibitory imaging strategy for visualizing in vivo protease activity would aid in determining patient prognosis and designing personalized protease-based inhibitors and prodrugs for targeted therapy. Here we developed an imaging strategy based on the conversion of a non-inhibitory protease substrate probe (PEG-peptide- 
INTRODUCTION
Proteases are involved in tumor formation, angiogenesis, local invasion and metastatic spread (1) (2) (3) . Members of the matrix metalloproteinase (MMP) family contribute to the invasion and metastasis of bladder cancer, fibrosarcoma, breast cancer and colon cancer (4, 5) . Given their relevance in cancer biology, proteases are attractive targets for the design of anti-cancer drugs that act preferentially at cancer sites. In line with this notion, several protease inhibitors, such as the MMP inhibitors Marimastat (6), AG3340 (7), S-3304 (8) and , have entered phase I, II and III clinical trials for cancer therapy. In addition, many protease substrate prodrugs have been reported to inhibit the growth of several cancer types in vivo (10, 11) . On the other hand, many studies have also shown a clear correlation between protease expression and poor prognosis of cancer patients (12) (13) (14) , indicating proteases may be useful as markers to predict tumor recurrence and prognostic survival. Thus, tumor-associated proteases seem attractive as both therapeutic targets and prognosis markers. Therefore, the technology to image protease activity in vivo would provide a valuable tool to design personalized, protease activity-based prodrug therapies and to monitor tumor recurrence and patient prognosis. Radiolabeled protease inhibitors could bind to the catalytic site of MMP2/9 (19, 20) and MMP14 (21) for in vivo imaging. However, inhibitor-based imaging agents may bind indiscriminately to both the active and latent form of proteases which may lead to inaccurate interpretation of protease activities. Furthermore, these inhibitor-based imaging agents may inhibit protease activity in vivo, excluding the concurrent application for protease-based prodrugs targeted therapy. Therefore, development of a non-inhibitory yet highly sensitive and specific activity-based PET imaging probe is desirable to improve cancer patient management.
To overcome these challenges, we linked a hydrophilic polyethylene glycol (PEG 5000 ) molecule to the N-terminus of a MMP2/9 peptide substrate (GPLGVR) (22) , then attached PEG-peptide to a hydrophobic tetramethylrhodamine group (TMR) and finally labeled 18 F to form a PEG-peptide-18 F-TMR probe (Fig. 1 
Materials and Methods

Cells and Animals
The human fibrosacroma cell line HT1080 and the human breast adenocarcinoma cell line MCF-7 were purchased from the American Type Culture Collection Research. 
Statistical Analysis
Statistical significance of differences between mean values was estimated with InStat software (version 3.0; GraphPad Software) using the independent Student's t test for unequal variances. P-values of less than 0.05 were considered statistically significant.
Research. 
Results
Hydrolysis of peptide-TMR by MMP2 and MMP-expressing cells
To evaluate whether peptide-TMR could be selectively hydrolyzed by MMP, we incubated peptide-TMR (1618 Da) with purified MMP2 or conditioned medium from MMP-expressing HT1080 cells or control MCF-7 cells. The cleaved fragments of peptide-TMR were detected by matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF). We found that peptide-TMR (1618 Da, Figure   2A ) could be cleaved by purified MMP2 to release TMR (948 Da, Figure 2B ).
Treatment of peptide-TMR with culture medium from HT1080 cells produced similar results (Fig. 2C ) whereas medium from MCF-7 cells was unable to cleave peptide-TMR (Fig. 2D) . Cleavage of peptide-TMR was blocked by 1,10-phenanthroline, a broad-spectrum MMP inhibitor (23, 24) (Data not shown).
These results demonstrate that peptide-TMR can be selectively hydrolyzed by MMP2 and MMP-expressing cells.
In vitro imaging of PEG-peptide-TMR in MMP-expressing cells
The conversion of peptide-TMR by MMP may be used to detect MMP activity if the hydrophobic TMR moiety preferentially localizes or accumulates at sites displaying MMP activity. Thus we tested whether MMP-expressing HT-1080 cells could activate and retain TMR-derived fluorescence. Figure 3A Fig   1) .
Optical imaging of peptide-TMR activation and uptake of PEG-peptide-TMR at
MMP-expressing tumors in vivo
To investigate whether PEG-peptide-TMR could noninvasively image MMP activity in vivo, mice bearing HT1080 and MCF-7 tumors were intravenously injected with PEG-peptide-TMR. Figure 4A Research. Figure 5A shows that 36900 ± 8700 cpm accumulated at HT1080 cells, compared to 4100 ± 550 cpm at control MCF-7 cells (pዘ0.01). 
Micro-PET imaging of MMP activity in vivo
To evaluate whether PEG-peptide- suggesting that the PEG-peptide-18 F-TMR was preferentially hydrolyzed and accumulated in HT1080 tumors. Strong imaging intensity was observed in the kidneys of mice by PET, suggesting that the probe was eliminated via the urinary system (Supplementary Figure 2) . Moreover, radioactivity in the ROI was decreased by 1,10-phenanthroline treatment ( Figure 6B) ; following 1,10-phenanthroline treatment the radioactivity in the ROI was only 1.3-, 3.6-and 3.3-fold greater in HT1080 tumors than in MCF-7 tumors at 15, 60 and 120 min. These results indicate that PEG-peptide-18 F-TMR can be used to detect tumoral MMP activity in vivo by micro-PET.
Biodistribution of PEG-peptide-
18
F-TMR in vivo
HT1080 and MCF-7 tumor-bearing mice were i.ntravenously injected with PEG-peptide-18 F-TMR and the radioactivity in selected tissues was examined.
Greater radioactivity was retained at HT1080 tumors than at control MCF-7 tumors at every time point examined (Supplementary Figure 4) . Highest tumoral uptake of Research. 
Discussion
We successfully developed a non-inhibitory protease-substrate probe for PET imaging of protease activity based on the conversion of PEG-peptide- protease-expressing cells (33, 34) , MMP activity in the myocardium after myocardial infarction (35) and cathepsin B activity in osteoarthritis and rheumatoid arthritis (36) . In-DOTA for SPECT or Gd-DOTA for MRI, suggesting flexibility in choosing the optimal imaging system. We show here that MMP activity could be imaged by PET and optical imaging in vivo, implying that this strategy may be extended to other proteases in different diseases.
PET or SPECT imaging are considered to provide the highest sensitivity among 
